Gregory L.  Verdine net worth and biography

Gregory Verdine Biography and Net Worth

Director of WAVE Life Sciences

Gregory L. Verdine is one of Wave’s founders and has served on the board of directors since July 2013. Since 1989, Dr. Verdine has served as the Erving Professor of Chemistry in the Department of Stem Cell and Regenerative Biology and the Department of Chemistry and Chemical Biology at Harvard University and Harvard Medical School; he is now Erving Professor of Chemistry, Emeritus. Dr. Verdine co-founded the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy in 2013 and served as the Founding President until 2016. He is also President and Chief Executive Officer and serves on the board of directors of LifeMine Therapeutics Inc. Dr. Verdine is also the co-founder of Fog Pharmaceuticals and served in various roles from 2015 to 2024, including Vice Chairman of the Board of Directors, and is founder of Warp Drive Bio (merged with Revolution Medicines, Inc.) and served in various roles, including Chief Scientific Officer and Chief Executive Officer, from the company’s inception in 2012 until April 2016. Dr. Verdine founded Enanta Pharmaceuticals and served as a member of its board of directors from 1990 through its initial public offering in 2013. He has served as a Venture Partner at WuXi Healthcare Ventures, AppleTree Ventures, TPG Biotech and Third Rock Ventures, and he is currently a Venture Partner at Andreessen Horowitz. He has served on the Board of Scientific Counselors of the National Cancer Institute and on the Board of Scientific Consultants of the Memorial Sloan Kettering Cancer Center, and Harvard Medical School.

What is Gregory L. Verdine's net worth?

The estimated net worth of Gregory L. Verdine is at least $2.17 million as of August 22nd, 2025. Dr. Verdine owns 285,217 shares of WAVE Life Sciences stock worth more than $2,173,354 as of December 5th. This net worth evaluation does not reflect any other assets that Dr. Verdine may own. Learn More about Gregory L. Verdine's net worth.

How do I contact Gregory L. Verdine?

The corporate mailing address for Dr. Verdine and other WAVE Life Sciences executives is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. WAVE Life Sciences can also be reached via phone at (656) 236-3388 and via email at [email protected]. Learn More on Gregory L. Verdine's contact information.

Has Gregory L. Verdine been buying or selling shares of WAVE Life Sciences?

Gregory L. Verdine has not been actively trading shares of WAVE Life Sciences during the last quarter. Most recently, Gregory L. Verdine sold 10,000 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $10.00, for a transaction totalling $100,000.00. Following the completion of the sale, the director now directly owns 285,217 shares of the company's stock, valued at $2,852,170. Learn More on Gregory L. Verdine's trading history.

Who are WAVE Life Sciences' active insiders?

WAVE Life Sciences' insider roster includes Paul Bolno (CEO), Chris Francis (insider), Christian Henry (Director), Kyle Moran (CFO), Ken Takanashi (Director), and Gregory Verdine (Director). Learn More on WAVE Life Sciences' active insiders.

Are insiders buying or selling shares of WAVE Life Sciences?

In the last twelve months, insiders at the sold shares 8 times. They sold a total of 467,533 shares worth more than $4,461,142.90. The most recent insider tranaction occured on November, 13th when Director Adrian Rawcliffe sold 16,115 shares worth more than $109,420.85. Insiders at WAVE Life Sciences own 24.0% of the company. Learn More about insider trades at WAVE Life Sciences.

Information on this page was last updated on 11/13/2025.

Gregory L. Verdine Insider Trading History at WAVE Life Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/22/2025Sell10,000$10.00$100,000.00285,217View SEC Filing Icon  
6/13/2025Sell30,000$6.95$208,500.00282,517View SEC Filing Icon  
11/20/2019Sell30,039$30.63$920,094.5736,009View SEC Filing Icon  
11/14/2018Sell15,000$38.86$582,900.00View SEC Filing Icon  
6/15/2016Sell52,000$16.70$868,400.00150,079View SEC Filing Icon  
See Full Table

Gregory L. Verdine Buying and Selling Activity at WAVE Life Sciences

This chart shows Gregory L Verdine's buying and selling at WAVE Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

WAVE Life Sciences Company Overview

WAVE Life Sciences logo
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Read More

Today's Range

Now: $7.62
Low: $7.12
High: $7.68

50 Day Range

MA: $7.49
Low: $6.67
High: $9.04

2 Week Range

Now: $7.62
Low: $5.28
High: $15.72

Volume

2,519,503 shs

Average Volume

2,285,890 shs

Market Capitalization

$1.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A